Company: PSTV
Filing Date: 2025-07-21
Form Type: DEF 14A
Source: 0001140361-25-026611
Chunk: 0

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-07-21
Form: DEF 14A
Chunk 0
---
TABLE OF CONTENTS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant☐ Check the appropriate box:

| ☐ | Preliminary Proxy Statement |

| ☐ | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |

| ☒ | Definitive Proxy Statement |

| ☐ | Definitive Additional Materials |

| ☐ | Soliciting Material Pursuant under § 240.14a-12 |

PLUS THERAPEUTICS, INC. (Name of Registrant as Specified in Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box):

| ☒ |     | No fee required                                                                                      |
| ☐ |     | Fee paid previously with preliminary materials.                                                      |
| ☐ |     | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. |

TABLE OF CONTENTS

2710 Reed Road, Suite 160, Houston, TX 77002 (737) 255-7194 July 21, 2025 To Our Stockholders: In the last year, Plus Therapeutics made significant progress in advancing our radiotherapeutic pipeline. In addition, in mid-2024, we expanded our portfolio with our acquisition of CNSide®, a novel cerebrospinal fluid assay platform that enables the detection and management of central nervous system (CNS) cancers, a strategic complement to our therapeutic program. Our lead investigational radiotherapeutic drug, REYOBIQ™, is currently being evaluated for use in patients with three types of central nervous system cancers, specifically leptomeningeal metastases (LM), pediatric brain cancer (PBC), and recurrent glioblastoma (rGBM). Earlier in 2025, we completed the ReSPECT-LM safety trial and are now enrolling patients in a dose optimization trial intended to find a safe and effective dosing regime for REYOBIQ that we can incorporate in a US registrational trial. Also in 2025, the FDA cleared Plus Therapeutics to begin enrolling patients in our Phase 1/2